Abstract
The efficacy along with proper pharmacokinetics and toxicity profiling is the major determinants for the present scenario of successful drug development. The toxicity prospect accompanying weak ADMET (absorption, distribution, metabolism, elimination, and toxicity) profile are the vital justifications of late costly jeopardy of drug development. To predict the ADMET idiosyncrasy, in-silico inspection of some alpha-methylene-gamma-butyrolactones (2-7) was induced on the foundation of several physico-chemical criteria to predict their pharmacokinetic, pharmacodynamic, drug-likeness, bioactivity and molecular docking profile exploiting several computational tactics.